In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Growth differentiation factor 15 and n-terminal pro-b-type natriuretic peptide in the development of cardiorenal syndrome in patients with acute coronary syndrome

Session Poster Session 2

Speaker Associate Professor Irina Vishnevskaya

Event : Acute Cardiovascular Care 2015

  • Topic : basic science
  • Sub-topic : Basic Science
  • Session type : Poster Session

Authors : IR Vyshnevska (Kharkiv,UA), MP Kopytsya (Kharkiv,UA), OV Petyunina (Kharkiv,UA), OM Abolmasov (Kharkiv,UA), NV Tytarenko (Kharkiv,UA), NV Bila (Kharkiv,UA), AJ Yukhnovskiy (Kharkiv,UA)

Authors:
IR Vyshnevska1 , MP Kopytsya1 , OV Petyunina1 , OM Abolmasov1 , NV Tytarenko1 , NV Bila1 , AJ Yukhnovskiy1 , 1Government institution“L.T. Malaya Therapy National institute of the National academy of medical sci - Kharkiv - Ukraine ,

Citation:
European Heart Journal: Acute Cardiovascular Care ( 2015 ) 4 ( Supplement 5 ), S81

The development of cardiorenal syndrome proved worse prognosis in patients with acute coronary syndrome. The search for new biomarkers for the timely diagnosis of cardiorenal syndrome in combination with acute coronary syndrome continues.
Purpose: to determine the significance of Growth Differentiation factor 15 (GDF 15) and N-terminal pro-B-type natriuretic peptide (NT-pro BNP) in the prediction of the development of cardiorenal syndrome in patients with acute coronary syndrome.
Methods: we examined 70 patients with different forms of ACS: 54 men and 16 women, mean age was 61, 8 ± 1, 3 years. Among them, 38 patients with Q-wave myocardial infarction (Q-wave MI), 14 - with non-Q-wave myocardial infarction (non-Q-wave MI), 18 - unstable angina (UA). All patients had to undergo baseline investigations, including the level of serum creatinine, the glomerular filtration rate (GFR) was estimated using MDRD formula. In addition during the first day of hospitalization the GDF 15 and NT-pro BNP were determined. The endpoint was all-cause mortality. During a 6-month follow-up 11% patients died.
Results: during the statistical analysis the mean value of GDF 15 was 4607±1322 pg/ml, the mean value for NT- pro BNP was 803±310 pg/ml. After comparing the levels of NT- pro BNP and GDF 15 rank of correlation coefficient has been identified (r=0,5; p < 0,05), which corresponds to the communication of medium strength. Also, there was correlation between GDF 15 and NT-proBNP in the group of patients who died. In addition, GFR has been calculated, the average was 58 ml/min/1.73m2. Correlation analysis of the studied parameters showed significant negative correlation between the level of GFR and NT- pro BNP (r=−0,44; p <0,05), the same rank of correlation was between GFR and GDF 15. In the group of patients who died there was a strong relationship between GFR and NT – pro BNP (r= −0.6 p < 0.05) and GDF 15 (r= −0.7 p<0.05).
Conclusion: this study established a correlation between the level of GDF 15, NT – pro BNP and GFR, which makes it possible to use those markers in the diagnosis of cardiorenal syndrome.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are